Lazard Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Lazard Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$210K	Sell	21,000 -15,360	-42%	-$139K	﹤0.01%	1660
2026 Q1	$346K	Sell	36,360 -33,238	-48%	-$258K	﹤0.01%	1471
2025 Q4	$543K	Buy	69,598 +16,290	+31%	+$118K	﹤0.01%	1352
2025 Q3	$405K	Buy	53,308 +25,454	+91%	+$212K	﹤0.01%	1415
2025 Q2	$249K	Sell	27,854 -166,699	-86%	-$1.55M	﹤0.01%	1651
2025 Q1	$1.46M	Buy	194,553 +33,037	+20%	+$266K	﹤0.01%	1068
2024 Q4	$1.21M	Buy	161,516 +65,420	+68%	+$497K	﹤0.01%	1071
2024 Q3	$730K	Buy	+96,096	New	+$730K	﹤0.01%	1232
2024 Q2	–	Sell	-13,179	Closed	-$66K	–	2230
2024 Q1	$66K	Sell	13,179 -964	-7%	-$5.42K	﹤0.01%	1657
2023 Q4	$84K	Buy	+14,143	New	+$82K	﹤0.01%	1724
2023 Q2	–	Sell	-3,567	Closed	-$29K	–	2306
2023 Q1	$29K	Hold	3,567	–	–	﹤0.01%	1947
2022 Q4	$40K	Hold	3,567	–	–	﹤0.01%	1912
2022 Q3	$44K	Hold	3,567	–	–	﹤0.01%	1846
2022 Q2	$37K	Hold	3,567	–	–	﹤0.01%	1933
2022 Q1	$57K	Buy	+3,567	New	+$57.2K	﹤0.01%	1675
2021 Q4	–	Sell	-3,238	Closed	-$46K	–	2291
2021 Q3	$46K	Buy	+3,238	New	+$51.1K	﹤0.01%	1715
2020 Q2	–	Sell	-17,523	Closed	-$35K	–	1616
2020 Q1	$35K	Buy	+17,523	New	+$48.2K	﹤0.01%	1305

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Lazard Asset Management's BCRX Position: Q2 2026 in Review

Lazard Asset Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 42% in Q2 2026, selling an estimated $139K and leaving 21,000 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #1660.

Lazard Asset Management first reported a position in BCRX in Q1 2020 and has held it in 17 quarters since. The position peaked at $1.46M in Q1 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Lazard Asset Management held 21,000 shares of BioCryst Pharmaceuticals worth $210K as of Q2 2026.
Lazard Asset Management sold 15,360 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $139K.
BioCryst Pharmaceuticals made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1660 holding.
Lazard Asset Management first reported a position in BioCryst Pharmaceuticals in Q1 2020 and has held it in 17 quarters since.
Lazard Asset Management's BioCryst Pharmaceuticals position peaked at $1.46M in Q1 2025.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.